{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T07:30:05Z","timestamp":1767857405356,"version":"3.49.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2014,2,21]],"date-time":"2014-02-21T00:00:00Z","timestamp":1392940800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1007\/s10067-014-2528-z","type":"journal-article","created":{"date-parts":[[2014,2,20]],"date-time":"2014-02-20T01:34:05Z","timestamp":1392860045000},"page":"1049-1053","source":"Crossref","is-referenced-by-count":8,"title":["Increased incidence of liver enzymes abnormalities in patients treated with isoniazid in combination with disease modifying and\/or biologic agents"],"prefix":"10.1007","volume":"33","author":[{"given":"Josiane","family":"Bourr\u00e9-Tessier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mireia","family":"Arino-Torregrosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis","family":"Choquette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,2,21]]},"reference":[{"key":"2528_CR1","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/acr.21641","volume":"64","author":"JA Singh","year":"2012","unstructured":"Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM et al (2012) 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid Arthritis. Arthritis Care Res 64:625\u2013639","journal-title":"Arthritis Care Res"},{"key":"2528_CR2","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1136\/ard.2002.004598","volume":"62","author":"J Vanhoof","year":"2003","unstructured":"Vanhoof J, Landewe S, Van Wijngaerden E, Geusens P (2003) High incidence of hepatotoxicity of isoniazid treatment for tuberculosis chemoprophylaxis in patients with rheumatoid arthritis treated with methotrexate or sulfasalazine and antitumour necrosis factor inhibitors. Ann Rheum Dis 62:1241\u20131242","journal-title":"Ann Rheum Dis"},{"key":"2528_CR3","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00296-010-1571-6","volume":"32","author":"M Haroon","year":"2012","unstructured":"Haroon M, Martin U, Devlin J (2012) High incidence of intolerance to tuberculosis chemoprophylaxis. Rheumatol Int 32:33\u201337","journal-title":"Rheumatol Int"},{"key":"2528_CR4","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1164\/rccm.200510-1666ST","volume":"174","author":"JJ Saukkonen","year":"2006","unstructured":"Saukkonen JJ, Crohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM et al (2006) American Thoracic Society documents: an official ats statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 174:935\u2013952","journal-title":"Am J Respir Crit Care Med"},{"key":"2528_CR5","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1097\/FTD.0b013e31826a6306","volume":"34","author":"MG Anelli","year":"2012","unstructured":"Anelli MG, Scioscia C, Grattagliano I, Lapadula G (2012) Old and new rheumatic drugs and the risk of hepatotoxicity. Ther Drug Monit 34:622\u2013628","journal-title":"Ther Drug Monit"},{"key":"2528_CR6","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1471-2474-9-48","volume":"9","author":"P Jobanputra","year":"2008","unstructured":"Jobanputra P, Amarasena R, Maggs F, Homer D, Bowman S, Rankin E et al (2008) Hepatotoxicity associated with sulfasalazine in inflammatory arthritis: a case series from a local surveillance of serious adverse events. BMC Musculoskelet Disord 9:48","journal-title":"BMC Musculoskelet Disord"},{"key":"2528_CR7","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1177\/039463200902200234","volume":"22","author":"M Massarotti","year":"2009","unstructured":"Massarotti M, Marasini B (2009) Successful treatment with etanercept of a patient with psoriatic arthritis after adalimumab-related hepatotoxicity. Int J Immunopathol Pharmacol 22:547\u2013549","journal-title":"Int J Immunopathol Pharmacol"},{"key":"2528_CR8","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.jbspin.2007.12.009","volume":"75","author":"G Thi\u00e9fin","year":"2008","unstructured":"Thi\u00e9fin G, Morelet A, Heurgu\u00e9 A, Diebold MD, Eschard JP (2008) Infliximab-induced hepatitis: absence of cross-toxicity with etanercept. Joint Bone Spine 75:737\u2013739","journal-title":"Joint Bone Spine"},{"key":"2528_CR9","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s10067-006-0253-y","volume":"26","author":"AM Garc\u00eda Aparicio","year":"2007","unstructured":"Garc\u00eda Aparicio AM, Rey JR, Sanz AH, Alvarez JS (2007) Successful treatment with etanercept in a patient with hepatotoxicity closely related to infliximab. Clin Rheumatol 26:811\u2013813","journal-title":"Clin Rheumatol"},{"key":"2528_CR10","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1136\/ard.2007.076406","volume":"67","author":"A Mor","year":"2008","unstructured":"Mor A, Bingham CO, Kishimoto M, Izmirly PM, Greenberg JD, Reddy S et al (2008) Methotrexate combined with isoniazid treatment for latent tuberculosis is well tolerated in patients with rheumatoid arthritis: experience from an urban arthritis clinic. Ann Rheum Dis 67:462\u2013465","journal-title":"Ann Rheum Dis"},{"key":"2528_CR11","doi-asserted-by":"crossref","first-page":"S221","DOI":"10.1164\/ajrccm.161.supplement_3.ats600","volume":"161","author":"A Mor","year":"2000","unstructured":"Mor A, Bingham CO, Kishimoto M, Izmirly PM, Greenberg JD, Reddy S et al (2000) Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a joint statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med 161:S221\u2013S247","journal-title":"Am J Respir Crit Care Med"},{"key":"2528_CR12","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1001\/jama.1979.03290380015017","volume":"241","author":"RB Byrd","year":"1979","unstructured":"Byrd RB, Horn BR, Solomon DA, Griggs GA (1979) Toxic effects of isoniazid in tuberculosis chemoprophylaxis. Role of biochemical monitoring in 1,000 patients. JAMA 241:1239","journal-title":"JAMA"},{"key":"2528_CR13","first-page":"991","volume":"117","author":"DE Kopanoff","year":"1979","unstructured":"Kopanoff DE, Snider D, Caras G (1979) Isoniazid related hepatitis: a U.S. public health service cooperative surveillance study. Am Rev Respir Dis 117:991\u20131001","journal-title":"Am Rev Respir Dis"},{"key":"2528_CR14","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1378\/chest.123.1.102","volume":"123","author":"L McNeill","year":"2003","unstructured":"McNeill L, Allen M, Estrada C, Cook P (2003) Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis: improved completion rates but more hepatotoxicity. Chest 123:102\u2013106","journal-title":"Chest"},{"key":"2528_CR15","first-page":"486","volume":"164","author":"PS Millard","year":"1996","unstructured":"Millard PS, Wilcosky T, Reade-Christopher S, Weher D (1996) Isoniazid-related fatal hepatitis. West J Med 164:486\u2013491","journal-title":"West J Med"},{"key":"2528_CR16","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1001\/jama.281.11.1014","volume":"281","author":"CM Nolan","year":"1999","unstructured":"Nolan CM, Goldberg S, Buskin S (1999) Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA 281:1014\u20131018","journal-title":"JAMA"},{"key":"2528_CR17","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1378\/chest.128.1.116","volume":"128","author":"FF Fountain","year":"2005","unstructured":"Fountain FF, Tolley E, Chrisman CR, Self TH (2005) Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic. Chest 128:116\u2013123","journal-title":"Chest"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-014-2528-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-014-2528-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-014-2528-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T20:01:28Z","timestamp":1565208088000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-014-2528-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,21]]},"references-count":17,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["2528"],"URL":"https:\/\/doi.org\/10.1007\/s10067-014-2528-z","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,21]]}}}